Abstract
T cells expressing chimeric antigen receptors (CAR T cells) have demonstrated remarkable clinical efficacy in treating different hematologic tumors. However, several challenges must be overcome to allow similar efficiency against solid tumors. Among these challenges, two points are remarkable: the inefficient migration of LT CAR to tumor sites and the frequent local immunosuppression that…